False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay

Journal of Immunological Methods

Volumn 394, Issue 1-2, 2013, Pages 22-31

  Chen, Keguan ^a   Page, Jerry G ^a   Schwartz, Ann M ^a   Lee, Thomas N ^a   DeWall, Stephen L ^a   Sikkema, Daniel J ^a   Wang, Catherine ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

CD20; Cell membrane fragments; CLL; Drug target interference; Immunogenicity; Pre dose positives

Indexed keywords

CD20 ANTIGEN; FC RECEPTOR; OFATUMUMAB; RITUXIMAB;

ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; CELL MEMBRANE; CHEMOLUMINESCENCE; CONTROLLED STUDY; ELECTROCHEMILUMINESCENT BRIDGING ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOCHEMISTRY; IMMUNOGENICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ULTRACENTRIFUGATION;

ADA; ANTI-DRUG ANTIBODY; CD20; CELL MEMBRANE FRAGMENTS; CHRONIC LYMPHOCYTIC LEUKEMIA; CLL; CMFS; DRUG TARGET INTERFERENCE; ECL; ELECTROCHEMILUMINESCENT; IMMUNOGENICITY; MESO-SCALE DISCOVERY; MICROVESICLES; MSD; MVS; NC; NEGATIVE CONTROL; OFA; OFATUMUMAB; PC; POSITIVE CONTROL; PRE-DOSE POSITIVES; RITUXIMAB; RTX;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; FALSE POSITIVE REACTIONS; HUMANS; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL;

EID: 84880038044     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.04.011     Document Type: Article

References (35)

1. Alatrash G., Albitar M., O'Brien S., Wang X., Manshouri T., Faderl S., Ferrajoli A., Burger J., Garcia-Manero G., Kantarjian H.M., Lerner S., Keating M.J., Wierda W.G. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br. J. Haematol. 2009, 148:386.
2. Alduaij W., Illidge T.M. The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood 2011, 117:2993.
3. Barth M.J., Hernandez-Ilizaliturri F.J., Mavis C., Tsai P.C., Gibbs J.F., Deeb G., Czuczman M.S. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br. J. Haematol. 2011, 156:490.
4. Binder M., Otto F., Mertelsmann R., Veelken H., Trepel M. The epitope recognized by rituximab. Blood 2006, 108:1975.
5. Cang S., Mukhi N., Wang K., Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J. Hematol. & Oncol. 2012, 5:64.
6. Carrasco-Triguero M., Mahood C., Milojic-Blair M., Amaya C., Ruppel J., Hong K., Yi J.H., Kaur S. Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic. Bioanalysis 2012, 4:2013.
7. Ernst J.A., Li H., Kim H.S., Nakamura G.R., Yansura D.G., Vandlen R.L. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005, 44:15150.
8. Garcia-Chavez J., Majluf-Cruz A., Montiel-Cervantes L., Esparza M.G.R., Vela-Ojeda J. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann. Hematol. 2007, 86:871.
9. Ghosh A.K., Secreto C.R., Knox T.R., Ding W., Mukhopadhyay D., Kay N.E. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010, 115:1755.
10. Golay J.T., Clark E.A., Beverley P.C. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J. Immunol. 1985, 135:3795.
11. Gravanis I., Ersbøll J., Skovlund E., Abadie E., Marty M., Pignatti F. The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use. Oncologist 2010, 15:1335.
12. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676.
13. Jaglowski S.M., Alinari L., Lapalombella R., Muthusamy N., Byrd J.C. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010, 116:3705.
14. Kekow J., Mueller-Ladner U., Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure. Biologics: Targets and Therapy 2012, 6:191.
15. Klakamp S.L., Lu H., Tabrizi M., Funelas C., Roskos L.K. Application of analytical detection concepts to immunogenicity testing. Anal. Chem. 2007, 79:8176.
16. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., Barrett Y.C., Devanarayan V., Gorovits B., Gupta S., Parish T., Quarmby V., Moxness M., Swanson S.J., Taniguchi G., Zuckerman L.A., Stebbins C.C., Mire-Sluis A. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333:1.
17. Lee T.H., D'Asti E., Magnus N., Al-Nedawi K., Meehan B., Rak J. Microvesicles as mediators of intercellular communication in cancer-the emerging science of cellular 'debris'. Semin. Immunopathol. 2011, 33:455.
18. Lemery S.J., Zhang J., Rothmann M.D., Yang J., Earp J., Zhao H., McDougal A., Pilaro A., Chiang R., Gootenberg J.E., Keegan P., Pazdur R. U.S. food and drug administration approval: Ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin. Cancer Res. 2010, 16:4331.
19. Manshouri T., Do K.A., Wang X., Giles F.J., O'Brien S.M., Saffer H., Thomas D., Jilani I., Kantarjian H.M., Keating M.J., Albitar M. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003, 101:2507.
20. low expressing tumor cells that resist rituximab-mediated lysis. Haematologica 2010, 95(12). (95, 2063).
21. Mikulskis A., Yeung D., Subramanyam M., Amaravadi L. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J. Immunol. Methods 2011, 365:38.
22. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1.
23. Muralidharan-Chari V., Clancy J.W., Sedgwick A., D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Science 2010, 123:1603.
24. Oflazoglu E., Audoly L.P. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. mAbs 2010, 2:14.
25. Österborg A. Ofatumumab, a human anti-CD20 monoclonal antibody. Expert. Opin. Biol. Ther. 2010, 10:439.
26. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435.
27. Riley J.K., Sliwkowski M.X. CD20: a gene in search of a function. Semin. Oncol. 2000, 27(6 Suppl 12):17.
28. Robak T., Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011, 25:13.
29. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267.
30. Théry C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nuture Reviews Immunol 2009, 9:581.
31. U.S.Food and Drug Administration (FDA) Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins (Draft Guidance) December 2009, U.S. Department of Health and Human Services/Food and Drug Administration.
32. van Doormaal F.F., Kleinjan A., Di Nisio M., Büller H.R., Nieuwland R. Cell-derived microvesicles and cancer. The Netherlands J. of Medicine 2009, 67:266.
33. Wang Y., Mealy N., Bayés M. Ofatumumab. Drugs of the Future 2007, 32:408.
34. Zhang B. Mini-review: ofatumumab. mAbs 2009, 1:326.
35. Zhong Z.D., Dinnogen S., Hokom M., Ray C., Weinreich D., Swanson S.J., Chirmule N. Identification and inhibition of drug target interference in immunogenicity assays. J. Immunol. Methods 2010, 355:21.